Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience

U.K. retrospective chart review examined potential predictors of treatment response including age, baseline AKI severity and concomitant use of albumin in patients with HRS-AKI

PR Newswire

DUBLIN, Nov. 16, 2020 /PRNewswire/ — Mallinckrodt plc, a global biopharmaceutical company, today announced results from a post hoc analysis of a retrospective chart review study of terlipressin in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI) conducted in 26 hospitals in the United Kingdom. HRS-AKI, also known as HRS-1, is an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.1 Results were presented during a poster presentation at The Liver Meeting Digital Experience, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). The poster can be accessed here on the company’s website.

Terlipressin is an investigational product and its safety and effectiveness have not yet been established by the U.S. Food and Drug Administration.

The retrospective chart review study included 250 hospitalized adult patients from 26 centers in the U.K. with a diagnosis of HRS-AKI who received terlipressin or other vasopressors. The majority of patients were treated with terlipressin (n=203) and were evenly distributed by baseline AKI severity: mild, 33 percent (SCr <2.25 mg/dL); moderate, 36 percent (SCr ≥2.25 mg/dL and <3.5 mg/dL); severe, 31 percent (SCr ≥3.5 mg/dL). The overall response rate among patients treated with terlipressin, including complete responses (SCr ≤1.5 mg/dL) and partial responses (SCr reduction ≥20 percent but SCr >1.5 mg/dL), was 73 percent and differed between the mild and moderate (79 percent and 78 percent) groups compared to the severe group (60 percent). The retrospective chart review study identified absence of a precipitating event, concomitant use of albumin and mild or moderate baseline AKI severity as predictors of overall response. Presence of encephalopathy was the only predictor of mortality (hazard ratio, 2.77; 95 percent confidence interval, 1.56 to 4.92) identified by the study.2 

Other outcomes included need for dialysis, mortality, liver transplantation and adverse event rates. The limitations of this post hoc analysis of a retrospective chart review include a more heterogeneous HRS population than those in randomized clinical trials, sampling bias from conveniently selected enters, potential selection bias towards patients with known outcomes to the providers and under reporting of less severe adverse events.

“As a physician treating patients with difficult to treat conditions like HRS-1, it’s important to continue to build on decades of research of investigational products like terlipressin that can advance our scientific understanding of potential treatment options for these very sick patients,” said Kevin Moore, M.D., UCL Institute of Liver and Digestive Health, Royal Free Hospital, University College London.

Terlipressin is approved in many countries outside the United States, where it has been a standard of care for decades in the treatment of patients with HRS-1.3,4 Terlipressin, together with albumin, is currently the standard of care for HRS-1 in countries where it is available.5 

HRS-1 has a median survival time of approximately two weeks and greater than 80 percent mortality within three months if left untreated.6,7 At present, there are no drug therapies approved for the treatment of HRS-1 in the U.S. or Canada.8 HRS-1 is estimated to affect between 30,000 and 40,000 patients in the U.S. annually.9,10 

Mallinckrodt remains committed to furthering our understanding of HRS-1 and the potential of terlipressin to address HRS-1, a disease that is often a challenge to effectively diagnose,” said Steven Romano, M.D., Executive Vice President and Chief Scientific Officer at Mallinckrodt. “The results from this U.K. study add to the extensive knowledge and data of the investigational product in the U.S.”

This study was funded by Mallinckrodt.

About Terlipressin

Terlipressin is a potent vasopressin analogue selective for V1 receptors being investigated for the treatment of HRS-1 in the U.S. and Canada. It is an investigational product in these countries as the safety and efficacy have not been established with, nor has approval been granted by, regulatory authorities in either country. Terlipressin is approved for use outside the U.S. and Canada.

ABOUT MALLINCKRODT 

Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company’s Specialty Brands reportable segment’s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements with regard to terlipressin, including its potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; issues with product quality, manufacturing or supply, or patient safety issues; and other risks identified and described in more detail in the “Risk Factors” section of Mallinckrodt’s most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

CONTACT


Media Inquiries


Caren Begun

Green Room Communications
201-396-8551
[email protected]


Investor Relations


Daniel J. Speciale

Vice President, Finance and Investor Relations Officer
314-654-3638
[email protected]

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2020 Mallinckrodt. US-2000454 11/20


References

1 National Organization for Rare Disorders. Hepatorenal Syndrome. Available at: https://rarediseases.org/rare-diseases/hepatorenal-syndrome/. Accessed November 3, 2020.
2 Moore K, Jamil K, Verleger K, Kelkar S, Kebede N et al. Predictors of response to terlipressin in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI): A multicenter study. Poster presented at: The Liver Meeting Digital Experience; November 13-16, 2020; Boston, MA.
3 De Franchis R. Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43:167-176.
4 Ioannou GN, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database of Systematic Reviews. 2003;1. doi: 10.1002/14651858.CD002147.
5 European Association for the Study of the Liver (EASL). Clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.
6 Colle I and Laterre PF. Hepatorenal syndrome: the clinical impact of vasoactive therapy. Expert Review of Gastroenterology & Hepatology. (2018) 12:2, 173-188, DOI: 10.1080/17474124.2018.1417034. 
7 Gines P, Sola E, Angeli P, et al. Hepatorenal syndrome. Nature Reviews. (2018) 4:23. 
8 Boyer TD, Medicis JJ, Pappas SC, et al. A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials 2012:4. https://www.dovepress.com/a-randomized-placebo-controlled-double-blind-study-to-confirm-the-reve-peer-reviewed-article-OAJCT
9 C Pant, B S Jani, M Desai, A Deshpande, Prashant Pandya, Ryan Taylor, R Gilroy, M Olyaee. Hepatorenal syndrome in hospitalized patients with chronic liver disease: results from the Nationwide Inpatient Sample 2002–2012. Journal of Investigative Medicine. 2016;64:33–38.
10 United States Census Bureau: Quick Facts. Available at: https://www.census.gov/quickfacts/fact/table/US/PST045218. Accessed November 3, 2020.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-announces-data-from-a-multicenter-post-hoc-analysis-of-terlipressin-in-patients-with-hepatorenal-syndrome-acute-kidney-injury-hrs-aki-at-the-liver-meeting-digital-experience-301173285.html

SOURCE Mallinckrodt plc

EQT Announces Upsizing And Early Results Of Its Tender Offer

For up to $200 Million Combined Aggregate Principal Amount of its 4.875% Senior Notes due 2021 and 3.000% Senior Notes due 2022

PR Newswire

PITTSBURGH, Nov. 16, 2020 /PRNewswire/ — EQT Corporation (NYSE: EQT) (the “Company” or “EQT”) announced today that it has amended the terms of its previously announced tender offer (the “Tender Offer”) to purchase for cash up to an amended Maximum Tender Amount (as defined below) of its 4.875% Senior Notes due 2021 (the “2021 Notes”) and 3.000% Senior Notes due 2022 (the “2022 Notes” and, together with the 2021 Notes, the “Notes”). The Company also announced today the early results of the Tender Offer. 

The Company has amended the Tender Offer to (i) increase the combined aggregate principal amount of Notes subject to the Tender Offer (the “Maximum Tender Amount”) from $150,000,000 to $200,000,000 and (ii) limit the aggregate principal amount of 2022 Notes that may be accepted for purchase in the Tender Offer to $181,177,000 (the “2022 Notes Tender Cap”). All other terms of the Tender Offer remain unchanged.

Subject to the Maximum Tender Amount and the 2022 Notes Tender Cap, the amounts of each series of Notes to be purchased are being determined in accordance with the acceptance priority levels specified in the table below and on the cover page of the Offer to Purchase, dated October 30, 2020 (the “Offer to Purchase”), in the column entitled “Acceptance Priority Level” (the “Acceptance Priority Level”), with “1” having a higher Acceptance Priority Level than “2.”

The principal amount of each series of Notes that were validly tendered and not validly withdrawn as of 5:00 p.m., New York City time, on November 13, 2020 (the “Early Tender Date”) and the principal amount of each series of Notes that will be accepted for purchase by the Company on the Early Settlement Date (as defined below) are specified in the table below. Because the aggregate principal amount of 2022 Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date exceeded the 2022 Notes Tender Cap, the Company will accept the 2022 Notes for purchase on a pro rata basis based on the proration factor described in the Offer to Purchase. Withdrawal rights for the Tender Offer expired at 5:00 p.m., New York City time, on November 13, 2020. As a result, tendered Notes may no longer be withdrawn.


Title of Notes


CUSIP Number


Principal Amount Outstanding


Acceptance
Priority Level


Series


Tender Cap


Principal Amount
Tendered


Principal Amount
Accepted


Approximate Proration Factor(1)


Tender Offer Consideration (2)(3)


Early Tender
Premium(2)


Total Consideration (2)(3)(4)

3.000%
Senior
Notes due
2022

26884LAE9

$750,000,000

1

$181,177,000

$216,363,000

$181,177,000

83.8%

$955.00

$50.00

$1,005.00

4.875%
Senior
Notes due
2021

26884LAB5

$143,941,000

2

N/A

$18,823,000

$18,823,000

100.0%

$980.00

$50.00

$1,030.00

________

(1)

The proration factor for the 2022 Notes has been rounded to the nearest tenth of a percentage point for presentation purposes.

(2)

Per $1,000 principal amount of Notes accepted for purchase.

(3)

Does not include accrued and unpaid interest, which will also be paid in addition to the Tender Offer
Consideration or the Total Consideration, as applicable.

(4)

Includes the Early Tender Premium.

Payment for Notes accepted for purchase is expected to be made on November 17, 2020 (the “Early Settlement Date”). The Company’s obligation to accept for payment and to pay for the Notes validly tendered in the Tender Offer is subject to the satisfaction or waiver of a number of conditions described in the Offer to Purchase. 

Although the Tender Offer is scheduled to expire at 11:59 p.m., New York City time, on November 30, 2020, because holders of Notes validly tendered and did not validly withdraw Notes on or before the Early Tender Date in an amount that exceeds the Maximum Tender Amount, the Company does not expect to accept for purchase any tenders of Notes after the Early Tender Date. The Company reserves the right, subject to applicable law, to (i) waive any and all conditions to the Tender Offer, (ii) extend, terminate or withdraw the Tender Offer, (iii) increase or decrease the Maximum Tender Amount or the 2022 Notes Tender Cap, or (iv) otherwise amend the Tender Offer in any respect.

BofA Securities is acting as Dealer Manager for the Tender Offer. The Information Agent and Tender Agent is Global Bondholder Services Corporation.

Copies of the Offer to Purchase, the related Letter of Transmittal and other related Tender Offer materials are available by contacting the Information Agent at (866) 470-4500 (toll-free) or (212) 430-3774 (collect) or email [email protected]. Questions regarding the Tender Offer should be directed to BofA Securities at (980) 388-4370 (collect) or [email protected].

This news release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. The Tender Offer is being made only pursuant to the Offer to Purchase and only in such jurisdictions as is permitted under applicable law.

Investor Contact:

Andrew Breese

Director, Investor Relations
412.395.2555
[email protected]

About EQT Corporation
EQT Corporation is a leading independent natural gas production company with operations focused in the cores of the Marcellus and Utica Shales in the Appalachian Basin. We are dedicated to responsibly developing our world-class asset base and being the operator of choice for our stakeholders. By leveraging a culture that prioritizes operational efficiency, technology and sustainability, we seek to continuously improve the way we produce environmentally responsible, reliable and low-cost energy. We have a longstanding commitment to the safety of our employees, contractors, and communities, and to the reduction of our overall environmental footprint. Our values are evident in the way we operate and in how we interact each day – trust, teamwork, heart, and evolution are at the center of all we do.

Cautionary Statements
This news release contains certain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Statements that do not relate strictly to historical or current facts are forward-looking. Without limiting the generality of the foregoing, forward-looking statements contained in this news release specifically include statements regarding the Company’s plans and expected timing with respect to the Tender Offer. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from projected results. Accordingly, investors should not place undue reliance on forward-looking statements as a prediction of actual results. The Company has based these forward-looking statements on current expectations and assumptions about future events, taking into account all information currently available to the Company. While the Company considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks and uncertainties, many of which are difficult to predict and beyond the Company’s control. The risks and uncertainties that may affect the operations, performance and results of the Company’s business and forward-looking statements include, but are not limited to, volatility of commodity prices; the costs and results of drilling and operations; access to and cost of capital; uncertainties about estimates of reserves, identification of drilling locations and the ability to add proved reserves in the future; the assumptions underlying production forecasts; the quality of technical data; the Company’s ability to appropriately allocate capital and resources among its strategic opportunities; inherent hazards and risks normally incidental to drilling for, producing, transporting and storing natural gas, natural gas liquids and oil; cyber security risks; availability and cost of drilling rigs, completion services, equipment, supplies, personnel, oilfield services and water required to execute the Company’s exploration and development plans; the ability to obtain environmental and other permits and the timing thereof; government regulation or action; environmental and weather risks, including the possible impacts of climate change; uncertainties related to the severity, magnitude and duration of the COVID-19 pandemic; and disruptions to the Company’s business due to acquisitions and other significant transactions. These and other risks are described under Item 1A, “Risk Factors,” and elsewhere in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as updated by Part II, Item 1A, “Risk Factors” in the Company’s subsequently filed Quarterly Reports on Form 10-Q and other documents the Company files from time to time with the Securities and Exchange Commission. In addition, the Company may be subject to currently unforeseen risks that may have a materially adverse impact on it.

Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/eqt-announces-upsizing-and-early-results-of-its-tender-offer-301173192.html

SOURCE EQT Corporation

NICE and Symphony Partner to Drive Digital Transformation Through Rapid Adoption of Intelligent Attended Automation

NICE and Symphony Partner to Drive Digital Transformation Through Rapid Adoption of Intelligent Attended Automation

Partnership combines NICE’s innovative attended automation and AI capabilities with Symphony’s proven methodologies for rapid integration, enabling organizations to optimize the value of RPA

HOBOKEN, N.J.–(BUSINESS WIRE)–NICE (Nasdaq: NICE) today announced that it has partnered with Symphony, a Sykes company, to expand deployment of robotic process automation, and in particular attended automation, globally. The collaboration allows organizations worldwide to benefit from NICE’s industry-first employee virtual attendant, NEVA, together with Symphony’s holistic methodologies for RPA and intelligent automation design, implementation and adoption. This partnership ensures optimal use of automation in augmenting and complementing the human workforce and drives an all-encompassing approach to intelligent automation that ultimately boosts customer experiences.

The partnership brings together the complementary capabilities of NICE and Symphony, both native to the contact center and its IT environment. NICE brings its innovative contact center solutions portfolio, including NEVA, as well as the impressive scale of its automation footprint in the contact center, spanning tens of thousands of desktops. This goes hand in hand with Symphony’s proven methodologies and vast experience in helping leading enterprises integrate automation into their organization in a way that optimizes value throughout the entire customer lifecycle, from marketing to sales to care. The partnership enables organizations to benefit from NICE’s innovative RPA capabilities, including NEVA, that boost employee engagement and performance with Symphony’s proven, holistic best practices for adoption and risk management.

Barry Cooper, President, NICE Enterprise Group, said, “This partnership between NICE and Symphony enables organizations to optimally scale their intelligent automations and expand value for customers and employees. We’re pleased to partner with Symphony to help organizations discover and then maximize the benefits of smart attended automation for their businesses.”

Richard Mitchell, Chief Technology Officer of Symphony, a SYKES company, said, “We’re proud to collaborate with NICE to bring intelligent automation solutions that enrich employee experiences and create better customer interactions. Together, we look forward to increasing the number of scaled attended automation deployments at enterprises around the world that will help drive operating efficiencies across the front, middle and back offices resulting in significant enterprise-wide value.”

About NICE

NICE (Nasdaq: NICE) is the world’s leading provider of both cloud and on-premises enterprise software solutions that empower organizations to make smarter decisions based on advanced analytics of structured and unstructured data. NICE helps organizations of all sizes deliver better customer service, ensure compliance, combat fraud and safeguard citizens. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, are using NICE solutions. www.nice.com.

About Symphony, a SYKES company

Symphony, a SYKES company, is a professional services firm passionate about creating value for the world’s leading organizations by designing, delivering and managing digital business processes. As thought leaders, we have defined a proven methodology for strategic, at-scale deployment of Intelligent Automation (IA) solutions that drives results through digitized operations. Symphony has been named an RPA Service leader by HfS Research for four consecutive years – including being ranked #1 in Delivery of Value for 2018. For more information, visit http://www.symphonyhq.com and follow the company on LinkedIn or Twitter.

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Cooper, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

Corporate Media Contact

Christopher Irwin-Dudek, 201 561 4442, ET, [email protected]

Investors

Marty Cohen, +1 551 256 5354, ET, [email protected]

Yisca Erez +972 9 775 3798, CET, [email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Software Technology Electronic Design Automation

MEDIA:

Logo
Logo

Casper Reports Third Quarter 2020 Results

Casper Reports Third Quarter 2020 Results

COVID-19 and Supply Chain Impacted Third Quarter 2020 Revenue of $123.5 million

Continued Strength in Retail Partnership Channel, up 28% YoY

Gross Margins of 55.5%, up 480 basis points YoY

NEW YORK–(BUSINESS WIRE)–
Casper Sleep Inc. (“Casper” or the “Company”) (NYSE: CSPR) today announced financial results for the quarter ended September 30, 2020 (the “third quarter 2020” or “third quarter”).

Third Quarter 2020 Financial Highlights (as compared to the quarter ended September 30, 2019)

  • Revenue decreased 3.3% to $123.5 million;
  • North America revenue increased $2.2 million or 1.8%;
  • European revenue was negligible due to the closure of our European operations in the second quarter of 2020, compared to approximately $6 million in the quarter ended September 30, 2019;
  • Direct-to-Consumer Revenue decreased 11.4% to $89.9 million;
  • Retail Partnership Revenue increased 28.3% to $33.6 million;
  • Gross Profit increased 5.9% to $68.5 million with gross margin of 55.5%, up 480 basis points;
  • Net Loss improved $7.2 million or 31.1% to $15.9 million;
  • Adjusted EBITDA loss improved by $9.3 million or 55% to $7.5 million; and
  • Cash and cash equivalents of $96.1 million at quarter end.

Philip Krim, Chief Executive Officer, comments: “Casper’s third quarter was highly productive but unfortunately we believe the results don’t fully reflect the health and potential of our business. We saw record interest for our products evidenced by record website traffic, continued to drive gross margin expansion and progress towards profitability, and had another sequential quarter of growth; however, our top-line growth was disappointing based on the initial demand signals. Challenges in our supply chain, including industry-wide shortages in textiles and chemicals critical to foam production, led to significant out-of-stock inventory both in our direct-to-consumer and retail partnership channels. Many of our core mattresses were out of stock on our website for weeks at time and we were unable to monetize the full demand from retail partners leading to cancelled orders.

We have made significant progress addressing some of our supply chain challenges. Specifically, we have on-boarded new Tier 1 and Tier 2 suppliers and vendors; we are putting in place redundancies across key supply chain points and implementing improved inventory planning; and we are actively building up our safety stock which will help protect against further disruptions. We believe the worst of our supply chain disruptions are behind us, and we are well-positioned going forward.”

Mr. Krim continued: “We are actively managing the business to best position Casper for the future and are excited about the many opportunities in front of us to enhance shareholder value as we continue to leverage our leading brand and scale our multi-channel distribution. Our organization is focused on long-term, sustainable growth and we believe our expanded distribution, current growing product offering and pipeline, strong brand awareness, refined marketing expertise and healthy balance sheet position us well to achieve our goal of sustainable Adjusted EBITDA profitability starting in mid-2021.”

Third Quarter 2020 Review (all comparisons to the three months ended September 30, 2019)

Revenue was $123.5 million, a decrease of $4.2 million, or 3.3%, compared to $127.7 million. North America revenue increased $2.2 million or 1.8%, while our European operations, which closed at the end of the second quarter of 2020, had negligible revenue compared to revenue of $6.4 million for the three months ended September 30, 2019. Direct-to-consumer sales decreased 11.4% driven by the closure of our European operations and limited store offerings in response to public health and government orders and depressed retail foot traffic due to the COVID-19 pandemic, partially offset by a modest increase in North America e-commerce sales. North America direct-to-consumer revenue decreased by $6.1 million or 6.3%. We ended the third quarter with a retail presence of 65 stores, an increase of 17 net new stores compared with our retail footprint in the third quarter of 2019, with 64 of our 65 stores open and operating as of the end of the third quarter. Total retail partnership revenue increased by $7.4 million, or 28.3%, to $33.6 million driven by growth of sales activity with existing partners and the introduction of 7 new partners compared to the same period in the prior year. We ended the quarter with 21 partners, and an expanded range of product offerings. North America retail partnership revenue increased $8.3 or 32.6%. Additionally, during the third quarter 2020, we believe our revenue was negatively impacted by supply chain constraints that extended the time required to fulfill customer orders and resulting in lost orders. We have taken active measures which we expect to mitigate these supply chain issues in future quarters.

Gross profit was $68.5 million, an increase of $3.8 million, or 5.9%, compared to $64.7 million. Gross margin of 55.5% increased 480 basis points compared to 50.7%. The increase in gross margin was primarily driven by favorable product mix related to our new mattress line launched in March 2020, as well as lower logistics costs due to a change in service provider. Gross margin also benefited from an 80 basis point partial reversal of a charge taken in the first quarter of 2020 associated with a change in logistics providers.

Sales and marketing expenses were $42.6 million, a decrease of $2.0 million, or 4.5%, compared to $44.6 million. Sales and marketing expenses decreased due to reduced advertising spend resulting from lower online and offline media costs and improved marketing efficiencies. Sales and marketing expenses as a percentage of revenue decreased 40 basis points to 34.5% from 34.9%.

General and administrative expenses, which include store operating costs, were $39.5 million, a decrease of $1.8 million, or 4.3% , compared to $41.3 million. General and administrative expenses decreased primarily due to lower payroll costs and lower operating expenses associated with our corporate workforce working from home and limited store operations, partially offset by increased expenses related to being a public company. General and administrative expenses as a percentage of revenue decreased from 32.4% to 32.0%.

The Company recorded restructuring expenses of $0.2 million related to previously announced steps to reduce our cost structure and exit our European operations.

Net loss was $15.9 million, a decrease of $7.2 million, or 31.1%, compared to a net loss of $23.0 million.

Adjusted EBITDA loss was $7.5 million, a 55% improvement of $9.3 million compared to a loss of $16.8 million. See below for a reconciliation of Adjusted EBITDA to the most directly comparable measure calculated in accordance with GAAP, net loss.

Balance Sheet

As of September 30, 2020, the Company had cash and cash equivalents of $96.1 million, compared to $67.6 million as of December 31, 2019. The increase was driven primarily by $88.0 million in net proceeds from our initial public offering, partially offset by $47.0 million of cash used in operating activities and $12.6 million invested in property and equipment, primarily to build retail stores.

Recent Initiatives

Our Casper retail stores remain critical to our multi-channel strategy, providing our customers the opportunity to experience our products before making a purchase. Since the temporary closure of all our retail stores in North America in mid-March 2020, we have reopened all of our 66 total stores as of the date of this release, with each offering walk-in shopping, private in-store appointments, curbside pick-up services, as well as virtual appointments. As part of our retail operations, we have implemented and continuously update a suite of COVID-19-related operating policies and protocols, including providing modified service offerings where advisable, with the health and safety of our customers and employees as our top priority. We have also developed procedures to enable us to responsibly and efficiently open or close our stores and adjust our service offerings as needed in response to changing COVID-19 conditions and applicable guidance from government and public health officials.

We continued to see strong demand for our products on our e-commerce platform and from our retail partners in the third quarter. COVID-19-related supply constraints and labor shortages experienced by certain of our suppliers and logistics partners, coupled with the lean levels of safety stock inventory we generally maintain as part of our flexible manufacturing model, resulted in increased delivery times for certain products on our website and impacted order fulfillment for certain of our retail partners. As a result, during the third quarter, sales in our e-commerce and retail partnership channels were meaningfully impacted by product and delivery supply chain constraints. We are actively qualifying and on-boarding new suppliers, working in close partnership with existing suppliers to re-build safety stock inventory levels, and enhancing internal inventory planning and monitoring capabilities. Taken together, we expect these actions and additional capacity to significantly mitigate inventory constraints in future quarters.

Outlook

The Company today provided an outlook for certain financial metrics for the quarter ended December 31, 2020 (the “fourth quarter 2020”), reflecting certain assumptions by management regarding the Company’s business, trends, historical seasonal factors, and the continuing impact of the COVID-19 pandemic on its business. In addition, the outlook assumes there will be no material changes in world events, weather, recent consumer trends, economic conditions, competitive landscape or other circumstances beyond our control that may adversely affect the Company’s results of operations.

In the fourth quarter 2020, the Company expects revenue of approximately $132 to $142 million, driven by year-over-year growth in the Company’s e-commerce channel and the expansion of its retail partnerships. At the mid-point, this range represents high single-digit consolidated growth and double-digit year-over-year growth for its North America business in the fourth quarter 2020.

Conference Call & Webcast Information

Casper will hold a conference call on Monday, November 16, 2020, at 8:00 a.m. Eastern time to discuss the Company’s third quarter results and other business updates. To access the conference call, interested parties may dial 866-319-1799 (for domestic callers) or 825-312-2362 (for international callers). Please call at least five minutes in advance of the start of the call to ensure that you are connected prior to the call. Interested parties may also access a live audio webcast of the call at https://ir.casper.com/news-and-events/events-and-presentations/default.aspx. Please allow 15 minutes to register. A replay of the call will be available within two hours of the conclusion of the call until January 16, 2021 at https://ir.casper.com/news-and-events/events-and-presentations/default.aspx.

Casper periodically provides information for investors on its corporate website, casper.com, and its investor relations website, ir.casper.com. This includes press releases and other information about financial performance, reports filed or furnished with the SEC and information on corporate governance.

About Casper

Casper believes everyone should sleep better. The Sleep Company has a full portfolio of obsessively engineered sleep products—including mattresses, pillows, bedding, and furniture designed in-house by the Company’s award-winning R&D team at Casper Labs. In addition to its e-commerce business, Casper owns and operates Sleep Shops across North America and its products are available at a growing list of retailers.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the impact of the COVID-19 pandemic and the related effect on our employees, customers and business operations; our expectations surrounding our ability to deliver growth, gain market share, and improve profitability; anticipated cost savings as a result of our restructuring initiatives; our planned openings and closures of our retail stores; our on-boarding of new suppliers and the effects on our inventory constraints; our future competitive position; our future results of operations and financial position including our outlook for the fourth quarter 2020; our business strategy and plans, and objectives of management for future operations and creating long-term value. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the COVID-19 pandemic could adversely impact our business, financial condition and results of operations; our ability to compete successfully in the highly competitive industries in which we operate; our ability to maintain and enhance our brand; the success of our retail store expansion plans; our ability to successfully implement our growth strategies related to launching new products; the effectiveness and efficiency of our marketing programs; our ability to manage our current operations and to manage future growth effectively; our past results may not be indicative of our future operating performance; our ability to attract new customers or retain existing customers; the growth of the market for sleep as a retail category and our ability to become a leader or maintain our leadership in the category; the impact of social media and influencers on our reputation; our ability to protect and maintain our intellectual property; our exclusive reliance on third-party contract manufacturers whose efforts we are unable to fully control; our ability to effectively implement strategic initiatives; our ability to transfer our supply chain and other business processes to a global scale; risks relating to our international operations and expansion; we are dependent on our retail partners; general economic and business conditions; we could be subject to system failures or interruptions and security breaches; risks relating to changing legal and regulatory requirements, and any failure to comply with applicable laws and regulations; we may be subject to product liability claims and other litigation; we may experience fluctuations in our quarterly operating results; we have and expect to continue to incur significant losses; risks relating to our indebtedness; our need for additional funding, which may not be available; risks relating to taxes; future sales by us our stockholders may cause the market price of our stock to decline; and risks and additional costs relating to our status as a new public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, as updated by the “Risk Factors” section of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Non-GAAP Financial Measures

Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or any other performance measure derived in accordance with GAAP.

We define Adjusted EBITDA as net loss before net interest expense, income tax expense and depreciation and amortization as further adjusted to exclude the impact of stock-based compensation expense, restructuring expenses, legal settlements, and expenses incurred in connection with our initial public offering. We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by our competitors, because not all companies and analysts calculate Adjusted EBITDA in the same manner. We present Adjusted EBITDA because we consider them to be important supplemental measures of our performance and believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Management believes that investors’ understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations.

Management uses Adjusted EBITDA:

  • as a measurement of operating performance because it assists us in comparing the operating performance of our business on a consistent basis, as it removes the impact of items not directly resulting from our core operations;
  • for planning purposes, including the preparation of our internal annual operating budget and financial projections;
  • to evaluate the performance and effectiveness of our operational strategies; and
  • to evaluate our capacity to expand our business.

By providing this non-GAAP financial measure, together with the reconciliation, we believe we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for net income or other financial statement data presented in our consolidated financial statements as indicators of financial performance. Some of the limitations are:

  • such measures do not reflect our cash expenditures;
  • such measures do not reflect changes in, or cash requirements for, our working capital needs;
  • although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future and such measures do not reflect any cash requirements for such replacements; and
  • other companies in our industry may calculate such measures differently than we do, limiting their usefulness as comparative measures.

Due to these limitations, Adjusted EBITDA should not be considered as measures of discretionary cash available to us to invest in the growth of our business. We compensate for these limitations by relying primarily on our GAAP results and using these non-GAAP measures only supplementally. As noted in the Reconciliation of Non-GAAP metrics table elsewhere in this press release, Adjusted EBITDA includes adjustments to exclude the impact of stock-based compensation expense and material infrequent items, including but not limited to the costs of our initial public offering and restructuring costs, among other items. It is reasonable to expect that these items will occur in future periods. However, we believe these adjustments are appropriate because the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our business and may complicate comparisons of our internal operating results and operating results of other companies over time. In addition, Adjusted EBITDA includes adjustments for other items that we do not expect to regularly record following our initial public offering. Each of the normal recurring adjustments and other adjustments described in this paragraph and in the Reconciliation of Non-GAAP metrics table elsewhere in this press release help management with a measure of our core operating performance over time by removing items that are not related to day-to-day operations.

Casper Sleep Inc. and Subsidiaries

Consolidated Balance Sheets

(In thousands, except per share amounts)

(Unaudited)

 

Assets

September 30, 2020

 

December 31, 2019

Current assets:

 

 

 

Cash and cash equivalents

$

96,128

 

 

$

67,578

 

Accounts receivable, net

 

17,574

 

 

 

31,059

 

Prepaid expenses and other current assets

 

14,531

 

 

 

23,924

 

Inventory, net

 

34,269

 

 

 

39,358

 

Total current assets

 

162,502

 

 

 

161,919

 

Property and equipment, net

 

67,662

 

 

 

66,262

 

Other assets

 

2,682

 

 

 

2,137

 

Total assets

$

232,846

 

 

$

230,318

 

 

 

 

 

Liabilities, Convertible Preferred Stock and Stockholders’ Equity/(Deficit)

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

26,778

 

 

 

30,734

 

Accrued expenses

 

58,246

 

 

 

73,130

 

Deferred revenue

 

10,255

 

 

 

9,673

 

Other current liabilities

 

27,073

 

 

 

34,422

 

Total current liabilities

 

122,352

 

 

 

147,959

 

Other liabilities

 

74,368

 

 

 

69,492

 

Total liabilities

 

196,720

 

 

 

217,451

 

Convertible preferred stock

 

 

 

 

319,961

 

Stockholders’ equity/(deficit):

 

 

 

Common stock

 

 

 

 

 

Additional paid-in capital

 

436,360

 

 

 

18,097

 

Accumulated other comprehensive (loss) income

 

(447

)

 

 

69

 

Accumulated deficit

 

(399,787

)

 

 

(325,260

)

Total stockholders’ equity/(deficit)

 

36,126

 

 

 

(307,094

)

Total liabilities, convertible preferred stock and stockholders’ equity

$

232,846

 

 

$

230,318

 

Casper Sleep Inc. and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)

 

Three Months Ended

September 30,

Nine Months Ended

September 30,

 

 

2020

 

2019

 

2020

 

2019

Revenue

$

123,464

 

 

$

127,655

 

$

346,704

 

 

$

312,319

 

Cost of goods sold

 

54,944

 

 

 

62,942

 

 

168,155

 

 

 

157,342

 

Gross profit

 

68,520

 

 

 

64,713

 

 

178,549

 

 

 

154,977

 

Operating expenses

 

 

 

 

 

 

Sales and marketing expenses

 

42,565

 

 

 

44,551

 

 

113,220

 

 

 

113,994

 

General and administrative expense

 

39,518

 

 

 

41,311

 

 

128,522

 

 

 

105,445

 

Restructuring expenses

 

155

 

 

 

681

 

 

5,595

 

 

 

681

 

Total operating expenses

 

82,238

 

 

 

86,543

 

 

247,337

 

 

 

220,120

 

Loss from operations

 

(13,718

)

 

 

(21,830

)

 

(68,788

)

 

 

(65,143

)

Other (income) expense

 

 

 

 

 

 

Net interest expense

 

2,127

 

 

 

813

 

 

6,435

 

 

 

1,355

 

Other (income) expense, net

 

(9

)

 

 

287

 

 

(742

)

 

 

841

 

Total other expenses, net

 

2,118

 

 

 

1,100

 

 

5,693

 

 

 

2,196

 

Loss before income taxes

 

(15,836

)

 

 

(22,930

)

 

(74,481

)

 

 

(67,339

)

Income tax expense

 

20

 

 

 

93

 

 

46

 

 

 

60

 

Net loss

 

(15,856

)

 

 

(23,023

)

 

(74,527

)

 

 

(67,399

)

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

$

(0.40

)

 

$

(2.16

)

$

(2.07

)

 

$

(6.40

)

Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted

 

40,118,959

 

 

 

10,635,338

 

 

35,927,521

 

 

 

10,530,262

 

Casper Sleep Inc. and Subsidiaries

Consolidated Statement of Cash Flows

(In thousands)

(Unaudited)

 

 

Nine Months Ended

September 30,

 

 

2020

 

2019

Cash flows used in operating activities:

 

 

 

Net loss

$

(74,527

)

 

$

(67,399

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation and amortization

 

11,047

 

 

 

4,804

 

Stock based compensation expense

 

9,691

 

 

 

5,648

 

Other

 

2,328

 

 

 

4,287

 

 

 

 

 

Changes in assets and liabilities:

 

 

 

Accounts receivable, net

 

13,485

 

 

 

(1,273

)

Prepaid expenses and other current assets

 

9,393

 

 

 

(16,747

)

Inventory, net

 

4,484

 

 

 

5,585

 

Other assets

 

(552

)

 

 

52

 

Accounts payable

 

(3,843

)

 

 

2,973

 

Accrued expenses

 

(14,884

)

 

 

13,263

 

Deferred revenue

 

583

 

 

 

(3,219

)

Other liabilities

 

(4,191

)

 

 

22,320

 

Net cash used in operating activities

 

(46,986

)

 

 

(29,706

)

Cash flows used in investing activities:

 

 

 

Purchases of property and equipment

 

(12,559

)

 

 

(43,631

)

Note receivable

 

 

 

 

4,000

 

Net cash used in investing activities

 

(12,559

)

 

 

(39,631

)

Cash flows provided by financing activities:

 

 

 

Exercise of stock options and warrants

 

612

 

 

 

1,318

 

Proceeds from equity issuance

 

87,999

 

 

 

68,187

 

Proceeds from borrowings

 

 

 

 

29,225

 

Repayment on borrowings

 

 

 

 

(2,922

)

Net cash provided by financing activities

 

88,611

 

 

 

95,808

 

Effect of exchange rate changes

 

(516

)

 

 

75

 

Net change in cash and cash equivalents

 

28,550

 

 

 

26,546

 

Cash and cash equivalents at beginning of period

 

67,578

 

 

 

28,355

 

Cash and cash equivalents at end of the period

$

96,128

 

 

$

54,901

 

Casper Sleep Inc. and Subsidiaries

Reconciliation of Non-GAAP Metrics

(In thousands)

(unaudited)

 

 

Three months ended

September 30,

Nine months ended

September 30,

(in thousands)

2020

 

2019

2020

 

2019

Net loss

$

(15,856

)

 

$

(23,023

)

$

(74,527

)

 

$

(67,399

)

Income tax expense

 

20

 

 

 

93

 

 

46

 

 

 

60

 

Net interest expense

 

2,127

 

 

 

813

 

 

6,435

 

 

 

1,355

 

Depreciation and amortization

 

3,313

 

 

 

2,118

 

 

9,656

 

 

 

4,804

 

Stock based compensation(a)

 

3,746

 

 

 

2,122

 

 

9,691

 

 

 

5,648

 

Restructuring(b)

 

155

 

 

 

681

 

 

5,595

 

 

 

681

 

Legal settlements(c)

 

(1,000

)

 

 

 

 

500

 

 

 

138

 

Transaction costs(d)

 

 

 

 

383

 

 

787

 

 

 

906

 

Adjusted EBITDA

$

(7,495

)

 

$

(16,813

)

$

(41,817

)

 

$

(53,807

)

(a) Represents non-cash stock-based compensation expense.

(b) Represents costs associated with strategic shifts in our business structure including exiting certain lines of business and geographies. Associated costs include severance and other employee separation costs, contract termination expenses and asset impairment.

(c) Amounts related to litigation settlements.

(d) Represents expenses incurred for professional, consulting, legal, and accounting services performed in connection with our initial public offering, which are not indicative of our ongoing costs and which were discontinued following the completion of our initial public offering.

Press Contact

[email protected]

Investor Relations Contact

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Interior Design Online Retail Retail Other Retail Home Goods Construction & Property

MEDIA:

Logo
Logo

Ares Management Becomes Largest Single Shareholder in Peach Property Group AG

Ares Management Becomes Largest Single Shareholder in Peach Property Group AG

Ares Completes Conversion of Equity Interest and Joins Board of Directors of Leading Swiss-Listed Owner and Manager of German Residential Rental Assets

LOS ANGELES & LONDON–(BUSINESS WIRE)–
Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, announced today thata fund managed by its Real Estate Group has converted a CHF 155 million (€145 million) subordinated mandatory convertible bond (“MCB”) holding in Peach Property Group AG (“Peach”) (SIX: PEAN), a Swiss owner and manager of residential rental assets with approximately 23,000 residential units located across Germany.

Ares subscribed to its investment in the MCB in early October. The MCB was part of a CHF 230 million (€213 million) capital increase that Peach sought in order to strengthen its capital base and finance the acquisition of two substantial residential portfolios. Following the conversion, Ares is now the largest single shareholder of Peach with an approximate 30% interest in the company. In conjunction with Ares’ investment, Klaus Schmitz, Managing Director in the Ares Real Estate Group, was elected as a new member to the Board of Directors of Peach.

The investment is a continuation of Ares’ long-term commitment to the German residential market, in which it has been investing since 2013. Ares originated and structured the investment, drawing upon its ability to navigate complex public transactions and leverage its expertise across its integrated investment platform.

Peach is a vertically-integrated owner and manager of German residential assets. Since 2011, Peach has acquired and managed affordable housing in Germany and to date has accumulated a portfolio valued at close to CHF 2.0 billion (€1.9 billion), consisting of high-yielding investment properties in medium-sized cities in the larger metropolitan areas of Western Germany. Peach’s services range from property acquisition to active asset management, which includes letting and sale of properties. Peach employs a differentiated customer-centric business model building on twelve physical Peach Points (tenant stores) in core locations, which allows Peach to provide superior service to its clients while at the same time driving rental growth. With its headquarters in Cologne, Peach has approximately 135 full-time employees located throughout Germany and Switzerland. Peach has been listed on the SIX Swiss Exchange since 2010.

“Peach represents an exciting opportunity to access high-yielding residential assets in Germany with an attractive risk-adjusted return profile in a market benefitting from a structural supply and demand imbalance. We believe Peach’s assets are well positioned in one of the more defensive asset classes in Europe today whilst also benefitting from what we believe is a best-in-class management team and attractive growth trajectory for the company,” said John Ruane, Partner and Co-Head of European Real Estate Equity in the Ares Real Estate Group. “With over 20,000 residential units, Peach’s customer orientated business model and digital platform makes it a stand-out player in the German residential market.”

“As the new anchor shareholder of Peach, we aim to further grow the company and drive value for all of Peach’s shareholders,” said Klaus Schmitz. “We look forward to working with the management team to support further growth of Peach over the coming years.”

About Peach Property Group AG

The Peach Property Group is a property investor focused on residential investments in Germany. The Group stands for long time experience, competence and quality. Innovative solutions for modern housing needs, strong partnerships and a wide value chain complete the profile of the Group. The portfolio consists of mainly apartment properties, typically in close reach to major metropolitan areas. In addition, the Group develops properties for its own portfolio or for the sale as condominium. The business activities of the Group cover the entire value chain, from acquisition to active asset management and the sale or letting of the properties.

Peach Property Group AG is headquartered in Zurich and has its German Group headquarters in Cologne. Peach Property Group AG is listed on the SIX Swiss Exchange (PEAN, ISIN CH0118530366). Its Board of Directors consists of Reto Garzetti (President), Peter Bodmer, Dr. Christian De Prati, Kurt Hardt and – as representative of Ares – Klaus Schmitz. For more information, see www.peachproperty.com.

About Ares Management Corporation

Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager operating integrated groups across Credit, Private Equity, Real Estate and Strategic Initiatives. Ares Management’s investment groups collaborate to deliver innovative investment solutions and consistent, attractive investment returns for fund investors throughout market cycles. As of September 30, 2020, Ares Management’s global platform had approximately $179 billion of assets under management with more than 1,400 employees operating across North America, Europe and Asia Pacific. For more information, please visit www.aresmgmt.com.

About Ares Real Estate Group

The Ares Real Estate Group manages comprehensive public and private, equity and debt strategies with approximately $14.4 billion of assets under management and approximately 80 investment professionals, as of September 30, 2020. The real estate team maintains a time-tested and consistent investment approach across equity and debt strategies focusing on major property types that have value creation opportunities, located in liquid markets with diversified economies.

Media:

Mendel Communications

Bill Mendel, 212-397-1030

[email protected]

Ares Management Corporation

Priscila Roney, 212-808-1185

[email protected]

Brittany Cash, 212-301-0347

[email protected]

Investors:

Ares Management Corporation

Carl Drake, 800-340-6597

[email protected]

KEYWORDS: California New York Switzerland United States United Kingdom North America Europe Germany

INDUSTRY KEYWORDS: Professional Services Other Professional Services Other Construction & Property Residential Building & Real Estate Finance Construction & Property Banking

MEDIA:

Logo
Logo

Trane Technologies Named to Dow Jones Sustainability North America Index for Tenth Consecutive Year

Trane Technologies Named to Dow Jones Sustainability North America Index for Tenth Consecutive Year

SWORDS, Ireland–(BUSINESS WIRE)–
Trane Technologies (NYSE:TT), a global climate innovator, has been named to the Dow Jones Sustainability North America Index (DJSI), in the capital goods sector. This is the tenth consecutive year the company has achieved this prestigious ranking, and the first as Trane Technologies.

“It’s an honor to be recognized by DJSI as a company with a longstanding commitment to sustainability and a proven history of best-in-class environmental, social and governance practices,” said Mike Lamach, chairman and chief executive officer of Trane Technologies. “Sustainability is central to our strategy, core to how we operate, and embedded in every facet of our business. Our employees around the world are aligned to one purpose – to boldly challenge what’s possible for a sustainable world. I want to thank them for all they do to help our company, our customers and our industry to create positive change.”

The Dow Jones Sustainability Indices were the first global indices to track the leading sustainability-driven public companies based on an analysis of financially material environmental, social and governance factors. The indices serve as benchmarks for investors who integrate sustainability considerations into their portfolios and provide an engagement platform for companies seeking to adopt sustainable best practices. The Dow Jones Sustainability North America Index represents the top 20% of the largest 600 North American companies in the S&P Global BMI based on long-term economic, environmental and social criteria. Trane Technologies’ inclusion for the past decade underscores the company’s commitment to incorporating sustainable practices into every aspect of its business including leading by example in its own operations, solving for customers’ climate impact with the Gigaton Challenge, and creating opportunity for all.

Boldly Challenging What’s Possible

Trane Technologies, and its leading brands Trane and Thermo King, is helping solve for some of the world’s biggest sustainability challenges and inspiring industry change with its 2030 Sustainability Commitments. These commitments include a pledge to reduce customer greenhouse gas emissions by one gigaton (2% of the world’s annual emissions), carbon-neutral operations, gender parity in leadership and a workforce reflective of the communities it serves. Trane Technologies is also making a positive difference in the community with significant investments in healthy environments for learning, access to education and workforce development.

Earlier this year, Trane Technologies debuted as a company focused on climate innovation after completing its Reverse Morse Trust transaction with Gardner Denver, now known as Ingersoll Rand.

About Trane Technologies

Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. For more on Trane Technologies, visit tranetechnologies.com.

About S&P Dow Jones Indices

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

Media Contact:

Jennifer Regina

+1-630-390-8011

[email protected]

Investors Contact:

Zachary Nagle

+1-704-990-3913

[email protected]

KEYWORDS: Europe Ireland United Kingdom

INDUSTRY KEYWORDS: Environment Logistics/Supply Chain Management Other Construction & Property Transport Construction & Property Building Systems Other Transport

MEDIA:

Logo
Logo

Avalara Announces Code-Focused Virtual Event for Developers: Avalara NEXT

Avalara Announces Code-Focused Virtual Event for Developers: Avalara NEXT

SEATTLE–(BUSINESS WIRE)–Avalara (NYSE:AVLR), a leading provider of tax compliance automation software for businesses of all sizes, today announced its first code-focused event for global tax compliance designed exclusively for developers — Avalara NEXT. The completely virtual conference will take place January 27, 2021. Bringing together developers at the forefront of global commerce and tax technology, Avalara NEXT offers digital attendees the opportunity to learn about Avalara’s new products, APIs, tools, and best practices to help developers easily build tax compliance into their business applications.

“As businesses continue to grow through digital commerce, they’re running into increased tax compliance regulations on a global scale, creating the need for a next-generation tax compliance platform to manage expanding tax obligations,” said Sanjay Parthasarathy, Chief Product Officer at Avalara. “Avalara NEXT will provide a forum for developers to connect and learn about the technology and best practices to integrate global tax compliance with their business applications.”

Avalara NEXT attendees — including Avalara customers, independent software vendors, system integrators, technology partners, and other industry experts — will walk away with an understanding of the innovation taking place at the intersection of tax compliance and commerce, and will learn about the tools and technology necessary to build tax compliance into business applications.

Avalara NEXT highlights:

  • Live coding: Watch live coding demonstrations and learn how to build a tax integration to your business application in a few hours.
  • Technical thought leaders: Hear from Avalara’s senior technical experts to learn how to optimize Avalara integrations.
  • Partner success stories: Network with technology platform partners to learn how they’ve successfully leveraged Avalara’s solutions.
  • New solutions: Learn about new global solutions from Avalara to drive value and efficiencies for your customers.

For more information or to reserve your spot for Avalara NEXT, please visit avalaranext.com.

Follow Avalara:

  • Twitter: For Avalara NEXT news and event updates, follow @Avalara and join the conversations using #AvalaraNEXT.
  • Facebook: Like Avalara on Facebook to view updates from Avalara NEXT.

About Avalara

Avalara helps businesses of all sizes get tax compliance right. In partnership with leading ERP, accounting, ecommerce, and other financial management system providers, Avalara delivers cloud-based compliance solutions for various transaction taxes, including sales and use, VAT, GST, excise, communications, lodging, and other indirect tax types. Headquartered in Seattle, Avalara has offices across the U.S. and around the world in Brazil, Europe, and India. More information at avalara.com.

Media Contact

Tommy Morgan

[email protected]

540-448-7551

Investor Contact

Jennifer Gianola

Avalara

[email protected]

650-499-9837

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Technology Finance Other Retail Accounting Professional Services Software Internet Retail Online Retail

MEDIA:

Logo
Logo

Alarm.com to Participate in Upcoming Virtual Investor Conferences

Alarm.com to Participate in Upcoming Virtual Investor Conferences

TYSONS, Va.–(BUSINESS WIRE)–
Alarm.com Holdings, Inc. (Nasdaq: ALRM), the leading platform for the intelligently connected property, today announced that Steve Valenzuela, Chief Financial Officer, will participate in and/or host one-on-one investor meetings at the following upcoming virtual investor conferences: the Credit Suisse 24th Annual Technology Conference, the Imperial Security Investor Conference, the Northland Tech Virtual Conference, the Raymond James Technology Investors Conference, and the Barclays Global Technology, Media, and Telecommunications Conference.

Event Details:

Credit Suisse 24th Annual Technology Conference

Tuesday, December 1, 2020

Hosting Investor Meetings

Imperial Security Investor Conference

Wednesday, December 2, 2020

Hosting Investor Meetings

Northland Tech Virtual Conference

Monday, December 7, 2020

Fireside Chat at 8:00 a.m. ET

Raymond James Technology Investors Conference

Tuesday, December 8, 2020

Fireside Chat at 8:50 a.m. ET

Barclays Global Technology, Media, and Telecommunications Conference

Thursday, December 10, 2020

Fireside Chat at 9:30 a.m. ET

About Alarm.com Holdings, Inc.

Alarm.com is the leading platform for the intelligently connected property. Millions of consumers and businesses depend on Alarm.com’s technology to manage and control their property from anywhere. Our platform integrates with a growing variety of Internet of Things (IoT) devices through our apps and interfaces. Our security, video, access control, intelligent automation, energy management, and wellness solutions are available through our network of thousands of professional service providers in North America and around the globe. Alarm.com’s common stock is traded on Nasdaq under the ticker symbol ALRM. For more information, please visit www.alarm.com.

Investor Relations:

David Trone

Alarm.com

[email protected]

Media Relations:

Matt Zartman

Alarm.com

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Software Technology Security

MEDIA:

Logo
Logo

BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

– Presentation featured at The Liver Meeting® 2020, the AASLD Annual Meeting, details support for the design of phage therapy candidate BX003 –

NESS ZIONA, Israel–(BUSINESS WIRE)–
BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that phages identified by BiomX with a broad host range were able to target and eradicate 89 percent of distinct gut-harbored Klebsiella pneumoniae strains isolated from samples obtained from patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). The study included over 1,000 strains isolated from over 300 patients with (IBD) or (PSC). In addition, oral administration of selected phage demonstrated efficacy in reducing target bacterial load in an in vivo model.

“These results support the potential of a phage therapy approach for the treatment of both IBD and PSC, demonstrating the ability to identify and select phage with direct relevance to patients,” commented Eran Elinav, M.D., Ph.D., Professor in the Department of Immunology at the Weizmann Institute of Science, a scientific founder of BiomX and a scientific advisor. “Our analysis of these results has informed the design and broad host range of BX003, an orally delivered candidate phage therapy targeting Klebsiella pneumoniae for the treatment of both IBD and PSC.“

The results will be featured in a poster presentation at The Liver Meeting® 2020, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) taking place Nov. 13-16, 2020.Presentation details are as follows:

Title: Broad Host Range Bacteriophage for Reduction of Klebsiella Pneumoniae as Potential Therapy in Primary Sclerosing Cholangitis (PSC) (Poster #1230)

Lead Author: Maya Kahan-Hanum, Ph.D., BiomX

Presentations will be available at the Company’s website at https://www.biomx.com/publications-2/.

About BiomX

BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, colorectal cancer, and cystic fibrosis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Additional information is available at www.biomx.com.

Safe Harbor Language

This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when this press release discusses the potential of a phage therapy approach for treatment of certain medical conditions and the ability to identify and select phage with direct relevance to patients, BiomX is making forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, invest should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q and additional disclosures BiomX makes in its filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.

Noel Kurdi, BiomX

VP Investor Relations and Strategy

(646) 241-4400

[email protected]

Media contact:

Rich Allan, Solebury Trout

(646) 378-2958

[email protected]

KEYWORDS: United States North America Israel Middle East

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Clinical Trials

MEDIA:

SOTI Launches Aerospace Division

Collaboration with Ryerson University will bring together top researchers, scientists, engineers and academia to create and build the next generation of aerial drones and robotics research in Canada

MISSISSAUGA, Ontario, Nov. 16, 2020 (GLOBE NEWSWIRE) — SOTI, the world’s most trusted provider of mobility and IoT management solutions, today announced the launch of its new aerospace division, SOTI Aerospace, which will focus on advanced aerial drone and robotics research. Working with industry-leading researchers, scientists, engineers, and academia from around the world, SOTI will initially invest $20 million (USD) to fund its new aerospace division.

The new division will focus its research on vision systems for indoor environments, including self-learning, situational understanding, automatic location of people and objects, self-navigation, and smart avoidance. Initial applications will be focused on the medical sector and search & rescue operations.

As part of its commitment to innovation, SOTI is also announcing a multi-year collaboration with Ryerson University. This initiative will bring together SOTI’s top talent and Ryerson’s world-class researchers to focus on advancing aerospace research. Ryerson’s aerospace expertise will support SOTI’s research and development of aerial drone technology. SOTI will support a research chair in this field and provide real-world experience in applied aerospace technology for Ryerson students.

“SOTI Aerospace represents an exciting new era for the company and continues our commitment to invest in Canada’s technology ecosystem and work with the best and brightest minds around the world in aerial technology,” said Carl Rodrigues, President and CEO, SOTI. “Ryerson University is an ideal collaborator. Together, we aim to nurture talent and entrepreneurship, and ultimately leverage technology for good. We look forward to working together to develop aerospace innovations that enhance student education while also bringing new technology to market.”

“Ryerson University is pleased to join with SOTI to advance innovative aerospace research and technology in Canada,” said Mohamed Lachemi, Ryerson University President and Vice-Chancellor. “This collaboration unites leading aerospace researchers and industry experts, to accelerate the development of aerial drone research through dedicated funding. The agreement will also create new opportunities for our students to work on cutting-edge projects through enriched learning experiences, internships and scholarships.”

For over two decades, SOTI has been at the forefront of the mobile revolution. The new aerospace division will lean heavily on SOTI’s management team’s extensive engineering experience, as well as bring together the best and brightest from around the globe to reimagine how technology can be used to transform the world.

About SOTI

SOTI is the world’s most trusted provider of mobile and IoT management solutions, with more than 17,000 enterprise customers and millions of devices managed worldwide. SOTI’s innovative portfolio of solutions and services provide the tools organizations need to truly mobilize their operations and optimize their mobility investments. SOTI extends secure mobility management to provide an integrated solution to manage and secure all mobile devices and connected peripherals in an organization.

About Ryerson University
Ryerson University is Canada’s leader in innovative, career-oriented education. Urban, culturally diverse and inclusive, the University is home to more than 46,000 students, including 2,900 Master’s and PhD students, 3,800 faculty and staff, and over 200,000 alumni worldwide. Learn more at ryerson.ca.

For media inquiries, please contact:

SOTI Media Relations
[email protected]
1 (519) 998-1966